Cytos Biotechnology AG

Cytos developed immunodrugs, a new class of biopharmaceutical preparations for the prevention and treatment of chronic diseases, e.g. asthma. In 2002 the publicly listed company Asklia Holding AG was acquired by Cytos Biotechnology AG in a reverse IPO. Thanks to this merger Cytos registered on the stock exchange SIX. Cytos acquired all shares in Asklia, which was delisted and dissolved.